BioNxt Solutions (CSE:BNXT; OTC PINK:BNXTF; FSE:BXT) has announced that key milestones have been achieved in the development of BNT23001 for the treatment of multiple sclerosis (MS).
BNT23001 is BioNxt’s proprietary sublingual thin-film formulation of Cladribine.
In preclinical studies of BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic studies conducted in animal models, with toxicity studies showing no adverse local effects. Moreover, the company has transferred production of BNT23001 to Gen-Plus GmbH & Co., and has initiated patent nationalization in Europe, the U.S., and Canada.
According to BioNxt, this progress paves the way for clinical trials and regulatory submissions in 2025.
